ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,471.71
-0.28%
Dow Jones
39,122.48
0.74%
US Dollar vs MXN
18.36591
-0.37%
Brent Oil
85.095
0.47%
Bitcoin
64,976.91
0.01%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Syndax Pharmaceuticals Inc (SNDX)

  7. Syndax Pharmaceuticals Inc (SNDX) Noticias

SNDX Syndax Pharmaceuticals Inc

19.24
0.18 (0.94%)
Última actualización: 14:44:11
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Syndax Pharmaceuticals Inc SNDX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.18 0.94% 19.24 14:44:11
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
18.97 18.6875 19.39 19.06
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
17/6/202408:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202406:00PRNUSSyndax Presents Updated Positive Data from BEAT AML and..
10/6/202406:30GLOBEPyxis Oncology Expands Board of Directors with Appointment..
06/6/202406:00PRNUSSyndax Announces Plans to Advance into Phase 1b Portion of..
05/6/202406:00PRNUSSyndax Announces Participation at the Goldman Sachs 45th..
03/6/202415:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
16/5/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202415:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
15/5/202415:11EDGAR2Form 8-K - Current report
15/5/202415:05PRNUSSyndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D...
09/5/202406:00PRNUSSyndax Announces Participation at the Bank of America..
08/5/202406:06PRNUSSyndax Pharmaceuticals Reports First Quarter 2024 Financial..
08/5/202406:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202406:03EDGAR2Form 8-K - Current report
03/5/202415:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
01/5/202406:00PRNUSSyndax to Announce First Quarter 2024 Financial Results and..
10/4/202415:05PRNUSSyndax Announces Participation at the Stifel 2024 Virtual..
08/4/202406:00PRNUSSyndax Presents Positive Pediatric Data from Pivotal..
05/4/202415:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
28/3/202406:00PRNUSSyndax Announces Completion of Enrollment in AUGMENT-101..
26/3/202415:05PRNUSSyndax Announces FDA Priority Review of NDA for Revumenib..
18/3/202406:00PRNUSSyndax Announces Appointment of Steven Closter as Chief..
01/3/202415:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
27/2/202416:28EDGAR2Form S-3ASR - Automatic shelf registration statement of..
27/2/202416:21EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202415:05PRNUSSyndax Pharmaceuticals Reports Fourth Quarter and Full Year..
27/2/202415:03EDGAR2Form 8-K - Current report
26/2/202406:00PRNUSSyndax Announces Participation at Two Upcoming Investor..
20/2/202415:05PRNUSSyndax to Announce Fourth Quarter and Year-end 2023..
14/2/202411:50EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202406:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202420:44EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
01/2/202415:10PRNUSSyndax Announces Participation at Two Upcoming Investor..
05/1/202415:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
02/1/202415:05PRNUSSyndax Announces Presentation at 42nd Annual J.P. Morgan..
02/1/202406:00PRNUSSyndax Highlights Recent Updates and Anticipated 2024..
20/12/202307:40EDGAR2Form 8-K - Current report
19/12/202315:16PRNUSSyndax Announces Closing of Public Offering of Common Stock..
15/12/202316:29EDGAR2Form 8-K - Current report
15/12/202316:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/12/202322:07PRNUSSyndax Announces Pricing of $200 Million Public Offering of..
14/12/202315:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]

Su Consulta Reciente

NASDAQ
SNDX
Syndax Pharmaceuticals
NASDAQ
RXII
RXI Pharmaceuticals Corporation
UNSW3
ESOVETH
eSOV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados